Labetuzumab govitecan: Additional Phase I/II data

Interim data from 38 evaluable mCRC patients previously treated with >=1 irinotecan-containing regimen in the Phase II portion of an open-label, dose-escalation, U.S.

Read the full 236 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE